We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bi... Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's lead product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers. Show more
REDWOOD CITY, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), announced that the Company has received notice from the U.S. Food and Drug...
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral...
Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks...
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
REDWOOD CITY, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.21 | -3.80434782609 | 5.52 | 5.83 | 5 | 376780 | 5.30659362 | CS |
| 4 | 0.23 | 4.52755905512 | 5.08 | 5.83 | 4.15 | 703915 | 4.76202023 | CS |
| 12 | -5.41 | -50.4664179104 | 10.72 | 13.43 | 3.65 | 1333635 | 6.5324629 | CS |
| 26 | -9.8 | -64.8577101257 | 15.11 | 20.21 | 3.65 | 1156191 | 10.79080068 | CS |
| 52 | -17.69 | -76.9130434783 | 23 | 23.07 | 3.65 | 1009602 | 12.49373221 | CS |
| 156 | -8.05 | -60.254491018 | 13.36 | 43.69 | 2.84 | 538271 | 16.16698598 | CS |
| 260 | -14.69 | -73.45 | 20 | 43.69 | 2.84 | 505859 | 16.18821027 | CS |
Zraced1
2 months ago
giveit2me
7 months ago
Invest-in-America
1 year ago
Invest-in-America
1 year ago
TheFinalCD
1 year ago
Invest-in-America
1 year ago
Bbradley8
1 year ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
